Latest Regulatory Change News

CSL Limited reported a sharp 80% drop in net profit for the half year ended December 2025, driven by significant restructuring and impairment charges, yet maintained its growth guidance and dividend payout.

Commonwealth Bank of Australia’s latest Basel III Pillar 3 disclosures reveal steady capital adequacy ratios and proactive adaptation to evolving regulatory standards as of December 2025.

Macquarie Group reports solid 3Q26 results with robust profit growth across divisions and a strong capital surplus, underpinned by strategic technology investments and regulatory compliance.

Macquarie Group has reported a solid third quarter for FY26, with significant profit gains in asset management and capital divisions, alongside steady growth in banking services. The group maintains a strong capital buffer, positioning itself well despite a cautious economic outlook.

Bravura Solutions has raised its FY26 revenue and cash EBITDA guidance, reflecting robust project engagement and disciplined cost management. The company also plans increased investment in internal technology.

WAM Active Limited has launched a $51.4 million pro-rata entitlement offer at a 7.8% discount to the recent share price, alongside a $19.3 million institutional placement to meet strong investor demand. The capital raising aims to bolster the company’s proven Australian equity investment strategy while offering shareholders fully franked dividends on new shares.

Aroa Biosurgery’s latest business update reveals promising clinical outcomes from its Myriad trauma study and evolving reimbursement policies that could reshape its market position. The company also projects solid revenue growth for FY26, supported by strategic commercial initiatives.

Tissue Repair’s December quarter update reveals a cautious path forward for its Phase 3 TR987 trial amid slow patient recruitment, while its TR Pro+ product line gains momentum through a new distributor partnership and upcoming product launches.

WAM Active Limited has launched a $70.7 million entitlement offer at a 7.8% discount, complemented by a $19.3 million placement, following a stellar 40.6% year-to-date portfolio performance. The capital raise aims to fuel further investment in Australian equities.

Spectur Limited reported a 4.5% increase in quarterly revenue to $2.02 million and secured $2.15 million through a share placement to fund its AI-driven Sense-Think-Act platform development.

Orbital Corporation Ltd reports a stronger cash position and a strategic new order for its 350cc heavy fuel engine, signalling growth in both military and commercial UAV markets.

Avecho Biotechnology is on the cusp of completing patient dosing in its pivotal Phase III CBD insomnia trial, backed by a recent $2.5 million capital raise and patent allowances in the US and Europe.